Fate Therapeutics Inc
FATE0.956USD
-0.007-0.76%
收盘 09/15, 16:00（美东）报价延迟15分钟
109.59M总市值
亏损市盈率 TTM
关于 Fate Therapeutics Inc 公司
Fate Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司致力于为癌症和自身免疫性疾病患者提供一系列诱导性多能干细胞 (iPSC) 衍生的细胞免疫疗法。其专有的诱导性多能干细胞 (iPSC) 产品平台将人类 iPSC 的多重工程与单细胞选择相结合，以创建克隆主 iPSC 系。该公司的平台旨在克服使用患者或供体来源的细胞制造细胞疗法的众多限制。利用其专有的 iPSC 产品平台，该公司正在推进现成的、多重工程化的自然杀伤 (NK) 细胞和 T 细胞候选产品，这些产品经过选择性设计，结合了对细胞功能的新型合成控制。其 iPSC 衍生的、嵌合抗原受体 (CAR) 靶向的 NK 细胞和 T 细胞候选产品包括 FT819、FT522、FT576、FT825、FT819、FT522 等。
公司简介
公司代码FATE
公司名称Fate Therapeutics Inc
上市日期Oct 01, 2013
CEODr. Bahram Valamehr, Ph.D.
员工数量181
证券类型Ordinary Share
年结日Oct 01
公司地址12278 Scripps Summit Drive
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编92131
电话18588751803
网址https://fatetherapeutics.com/
公司代码FATE
上市日期Oct 01, 2013
CEODr. Bahram Valamehr, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.61K
-18.06%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
58.39K
-13.40%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.61K
-18.06%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
58.39K
-13.40%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Redmile Group, LLC
11.17%
ARK Investment Management LLC
8.94%
The Vanguard Group, Inc.
7.60%
BlackRock Institutional Trust Company, N.A.
7.47%
Citadel Advisors LLC
3.94%
其他
60.88%
持股股东
持股股东
占比
Redmile Group, LLC
11.17%
ARK Investment Management LLC
8.94%
The Vanguard Group, Inc.
7.60%
BlackRock Institutional Trust Company, N.A.
7.47%
Citadel Advisors LLC
3.94%
其他
60.88%
股东类型
持股股东
占比
Investment Advisor
29.67%
Investment Advisor/Hedge Fund
27.56%
Hedge Fund
11.10%
Research Firm
6.68%
Venture Capital
3.30%
Individual Investor
1.71%
Pension Fund
0.15%
Bank and Trust
0.11%
Family Office
0.10%
其他
19.62%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
418
107.82M
94.06%
-31.88M
2025Q1
445
110.00M
95.96%
-29.05M
2024Q4
487
105.43M
92.56%
-50.79M
2024Q3
521
119.20M
104.73%
-42.15M
2024Q2
531
125.64M
110.45%
-29.93M
2024Q1
543
126.44M
111.19%
-6.65M
2023Q4
556
99.29M
100.70%
-34.38M
2023Q3
581
100.01M
101.45%
-44.66M
2023Q2
611
113.36M
115.11%
-33.43M
2023Q1
624
117.20M
119.39%
-6.61M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Redmile Group, LLC
12.87M
11.23%
--
--
Mar 31, 2025
ARK Investment Management LLC
10.31M
9%
+10.31M
--
Mar 31, 2025
The Vanguard Group, Inc.
10.31M
8.99%
-22.58K
-0.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
7.32%
-99.57K
-1.17%
Mar 31, 2025
Citadel Advisors LLC
4.29M
3.74%
-93.10K
-2.12%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.38M
2.95%
--
--
Mar 31, 2025
Vestal Point Capital, LP
2.52M
2.19%
+50.85K
+2.06%
Mar 31, 2025
Baker Bros. Advisors LP
3.26M
2.84%
--
--
Mar 31, 2025
Acadian Asset Management LLC
2.47M
2.16%
+999.77K
+67.84%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.59M
2.26%
-306.82K
-10.59%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
WisdomTree BioRevolution Fund
0.61%
Invesco NASDAQ Future Gen 200 ETF
0.41%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
查看更多
WisdomTree BioRevolution Fund
占比0.61%
Invesco NASDAQ Future Gen 200 ETF
占比0.41%
iShares Micro-Cap ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.01%
ProShares Ultra Nasdaq Biotechnology
占比0.01%
Invesco Nasdaq Biotechnology ETF
占比0.01%
iShares Biotechnology ETF
占比0.01%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
Schwab U.S. Broad Market ETF
占比0%
iShares Genomics Immunology and Healthcare ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
